Malignant tumors of the uterine corpus: molecular background of their origin-Reference-Cited by-同舟云学术

Malignant tumors of the uterine corpus: molecular background of their origin

Published:2015-08-26 Issue:9 Volume:36 Page:6615-6621
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumor Biol.

Author:

Brany D.,Dvorska D.,Nachajova M.,Slavik P.,Burjanivova T.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13277-015-3824-1.pdf

Reference71 articles.

1. D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2009;116:131–9.

2. Zubor P, Kajo K, Stanclova A, et al. Human epithelial growth factor receptor 2 polymorphism and risk of fibroadenoma. Eur J Cancer Prev. 2008;17(1):33–8.

3. Galo S, Zubor P, Szunyogh N, et al. Sérové hladiny TNF u žien s endometriózou: prospektívna klinická štúdia. Ceska Gynekol. 2005;70(4):286–90.

4. Culbova M, Lasabova Z, Stanclova A, et al. Metylácia vybraných tumor-supresorových génov v benígnych a malígnych ovariálnych nádoroch. Ceska Gynekol. 2011;76(4):274–9.

5. Kudela E, Farkasova A, Visnovsky J. Amplification of 3q26 and 5p15 regions in cervical intraepithelial neoplasia. Acta Obstetrica Scandinav. 2014;93(10):s 997–1002.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature;Biomedicines;2022-10-13

2. A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer;Gynecologic Oncology;2021-05

3. Mortality prediction in women with corpus uteri cancer in Brazil: a 21-year analysis;ecancermedicalscience;2020-05-04

4. miRNAs 144-3p, 34a-5p, and 206 are a useful signature for distinguishing uterine leiomyosarcoma from other smooth muscle tumors;Surgical and Experimental Pathology;2019-02-04

5. Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials;Expert Opinion on Orphan Drugs;2016-12-05